Last reviewed · How we verify
Methotrexate plus ERB-041 for 12 weeks — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Methotrexate plus ERB-041 for 12 weeks (Methotrexate plus ERB-041 for 12 weeks) — Wyeth is now a wholly owned subsidiary of Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methotrexate plus ERB-041 for 12 weeks TARGET | Methotrexate plus ERB-041 for 12 weeks | Wyeth is now a wholly owned subsidiary of Pfizer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methotrexate plus ERB-041 for 12 weeks CI watch — RSS
- Methotrexate plus ERB-041 for 12 weeks CI watch — Atom
- Methotrexate plus ERB-041 for 12 weeks CI watch — JSON
- Methotrexate plus ERB-041 for 12 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Methotrexate plus ERB-041 for 12 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-plus-erb-041-for-12-weeks. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab